Ownership profile
Who owns Metagenics?
Metagenics, the nutritional supplements brand sold through healthcare practitioners, is privately owned and controlled by middle-market private equity firm Gryphon Investors (with co-investor Linden Capital Partners), following their acquisition of the company from Alticor (Amway's parent) in October 2021.
Ownership profile
Metagenics
Metagenics, Inc.
Evidence (10)
As recently as January 2026, Gryphon Investors is explicitly described as Metagenics' 'sponsor' in a press release about Metagenics acquiring Symprove and completing a strategic debt recapitalisation — confirming continued PE ownership as of early 2026
https://www.gryphon-inv.com/news/gryphon-investors-backed-metagenics-acquires-probiotic-brand-symprove/Gryphon Investors signed a definitive agreement to acquire Metagenics, Inc. from Alticor Inc. on October 18, 2021; Gryphon is identified as a middle-market private equity firm
https://www.gryphon-inv.com/news/gryphon-investors-announces-acquisition-of-metagenics/The official PR Newswire press release confirms Gryphon Investors acquired Metagenics, Inc. from Alticor Inc. and that Gryphon's deal team members joined the board
https://www.prnewswire.com/news-releases/gryphon-investors-announces-acquisition-of-metagenics-301401905.htmlLinden Capital Partners co-acquired Metagenics alongside Gryphon Investors on October 18, 2021, in a divestiture from Alticor
https://mergr.com/transaction/gryphon-investors-acquires-metagenicsGryphon Investors' own portfolio page lists Metagenics with a year invested of 2021, confirming current portfolio status
https://www.gryphon-inv.com/companies/metagenics/Linden Capital Partners' own portfolio page lists Metagenics as an active investment
https://www.linden.com/portfolio/investments/Greymontadvisors' verified October 2026 Gryphon portfolio snapshot confirms Metagenics remains active in Gryphon's portfolio, with the Symprove add-on (January 2026) listed as a recent deal
https://greymontadvisors.com/pe-firms/gryphon/Mergr confirms Metagenics is owned by private equity investors Gryphon Investors and Linden Capital Partners
https://mergr.com/company/metagenicsAlticor Inc. (parent of Amway) previously held a majority stake in Metagenics from approximately 2009 until the 2021 Gryphon acquisition
https://app.dealroom.co/companies/metagenicsShop Ethical records Gryphon Investors Inc. as owning 100% of Metagenics Inc., describing it as a middle-market private equity firm with ~$9B AUM
https://ethical.org.au/companies/1857What's uncertain
- The exact equity split between Gryphon Investors (lead) and Linden Capital Partners (co-investor) has not been publicly disclosed; Gryphon is consistently named as the controlling sponsor.
- Financial terms of the 2021 acquisition were not disclosed by either party.
- No public confirmation of a subsequent exit or secondary sale by Gryphon or Linden has been found as of October 2026; the January 2026 press release explicitly identifies Gryphon as sponsor, making an undisclosed exit unlikely but not impossible.
- Metagenics is a privately held company with no SEC reporting obligations; no Form D or state registry filing was independently verified in this search.